FDA Approves Dutrebis, Though It Is Not Commercially Marketed in U.S. at This Time

"On February 6, 2015, the FDA approved Dutrebis a fixed dose combination tablet containing 150 mg of lamivudine and 300 mg of raltegravir. Dutrebis tablet is approved for use in combination with other antiretroviral products for the treatment of HIV-1 infection in adults and pediatric patients greater than or equal to 6 years of age weighing at least 30 kg. …    "According to the manufacturer, Merck Pharmaceuticals, Dutrebis, will not be made commercially available in the U.S. at this time."   For more information, view the FDA news release.